Skip to main content

Regulatory Reliance — HSA's Framework

What is regulatory reliance?​

Regulatory reliance is the practice of one regulatory authority taking into account and giving weight to the assessment already conducted by another recognised authority, rather than duplicating the full review from scratch. Singapore's evaluation route system (Abridged, Expedited, Immediate) is a formal regulatory reliance framework built into the HP(MD) Regulations 2010.

HSA's reliance framework is distinct from:

  • Harmonisation: where two jurisdictions adopt identical requirements;
  • Mutual recognition: where two jurisdictions formally agree to accept each other's decisions;
  • Unilateral recognition: where one jurisdiction automatically accepts another's decision without any independent review.

Singapore's approach is unilateral reliance — HSA gives weight to reference agency approvals but retains its own evaluation function and decision-making authority.

How reliance works in practice​

When an applicant submits via the Abridged route, HSA:

  1. Verifies that the reference agency approval exists and is current;
  2. Confirms the approval is for the same device and same labelled use;
  3. Reviews a reduced set of technical documentation, relying on the reference agency's assessment for elements already reviewed;
  4. Applies its own Singapore-specific assessment where needed (e.g. checking labelling for Singapore market requirements).

The depth of HSA's residual review decreases as the number of qualifying approvals and years of safe marketing increase — hence the progression from Abridged → ECR/EDR → IBR.

HSA's regulatory reliance page​

HSA provides specific information on its regulatory reliance framework:

hsa.gov.sg/medical-devices/international-collaboration-medical-devices/regulatory-reliance

Strategic implications​

For overseas manufacturers, the key strategic insight is that the order in which regulatory approvals are obtained globally can significantly affect Singapore timelines and costs:

  • Getting CE + TGA before the Singapore submission enables ECR or IBR;
  • Getting FDA PMA + one other reference agency enables EDR for many Class D devices;
  • Submitting in Singapore first (before any reference agency approval) locks the applicant into the Full evaluation route.

See Singapore vs TGA / FDA / CE / Health Canada for a comparison framework.

Official sources​